Humana (HUM) Financial History
Review Humana annual and quarterly financial results, key ratios, insider transactions and SEC filing history in one chronological view. Data available from FY2007 through FY2025.
Financials
19 fiscal years, FY2007 to FY2025
Insider trades
451 trades
Risk factor changes
33 changes in the latest 10-K
Filings
Annual and quarterly reports
Compare
Side by side with another company
Humana Financial Statements
History since FY2007. Annual, in US dollars. Source: 10-K XBRL data.
Humana Revenue and Growth
Compare reported revenue and year-over-year revenue growth across available fiscal years.
Humana Income Statements
Review revenue, gross profit, operating income, net income and earnings per share.
Humana Balance Sheets
Review reported debt and book-value-based ratios where company data is available.
Humana Cash Flow Statements
Compare reported free cash flow across the available fiscal history.
Humana Financial Ratios
Compare net margin, price-to-earnings and price-to-book ratios by fiscal year.
| Fiscal year | FY2007 🔒 | FY2008 🔒 | FY2009 🔒 | FY2010 🔒 | FY2011 🔒 | FY2012 🔒 | FY2013 🔒 | FY2014 🔒 | FY2015 🔒 | FY2016 🔒 | FY2017 🔒 | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 | FY2022 | FY2023 | FY20248 new risk factorsInsiders net sold $749K | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $83.1B | $92.9B | $106.4B | $117.8B | $129.7B |
| Revenue growth | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | — | +11.8% | +14.5% | +10.7% | +10.1% |
| Gross profit | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | — | — | — | — | — |
| Operating income | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $3.1B | $3.8B | $4.0B | $2.6B | $2.7B |
| Net income | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $2.9B | $2.8B | $2.5B | $1.2B | $1.2B |
| Debt | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $12.5B | $11.1B | $11.7B | $11.7B | $12.4B |
| Free cash flow | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $0.9B | $3.5B | $3.0B | $2.4B | $0.4B |
| Net margin | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | 3.5% | 3.0% | 2.3% | 1.0% | 0.9% |
| EPS (diluted) | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $22.67 | $22.08 | $20.00 | $9.98 | $9.84 |
| P/E ratio | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | 20.5× | 23.2× | 22.9× | 25.4× | 26.0× |
| P/B ratio | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | — | — | — | — | — |
Daily closing prices, aggregated by calendar year.
| Year | 2000 🔒 | 2001 🔒 | 2002 🔒 | 2003 🔒 | 2004 🔒 | 2005 🔒 | 2006 🔒 | 2007 🔒 | 2008 🔒 | 2009 🔒 | 2010 🔒 | 2011 🔒 | 2012 🔒 | 2013 🔒 | 2014 🔒 | 2015 🔒 | 2016 🔒 | 2017 🔒 | 2018 🔒 | 2019 🔒 | 2020 🔒 | 2021 🔒 | 2022 | 2023 | 2024 | 2025 | 2026 (YTD) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Open | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $462.70 | $510.98 | $458.23 | $256.95 | $256.94 |
| Close | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $512.24 | $457.73 | $253.55 | $256.17 | $416.63 |
| High | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $571.09 | $541.22 | $475.15 | $315.21 | $455.75 |
| Low | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $351.56 | $423.37 | $213.66 | $206.78 | $163.26 |
| Annual return | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | +10.5% | -10.6% | -44.6% | +1.0% | +62.6% |
Humana Insider Transactions
From Form 4 filings. Showing the latest 5 of 451 trades.
| Traded | Filed | Insider | Type | Shares | Value | % of holdings |
|---|---|---|---|---|---|---|
| 2026-09-30 | 2026-10-02 | Kurt Hilzinger Director | Grant or award | 238 | $92K | — |
| 2026-09-01 | 2026-09-03 | Shantanu Nundy Chief Medical Officer | Grant or award (4 trades) | 10,196 | — | — |
| 2026-08-01 | 2026-08-04 | Paul John Smith Director | Grant or award (4 trades) | 2,176 | — | — |
| 2026-08-01 | 2026-08-04 | Frederick John Crawford Director | Grant or award (3 trades) | 1,632 | — | — |
| 2026-06-30 | 2026-07-02 | Kurt Hilzinger Director | Grant or award | 233 | $91K | — |
Humana Risk Factor Changes
Latest 10-K compared with the year before. 33 changes found.
We believe that certain of our customers place importance on our claims paying ability, financial strength, and debt ratings, and we may lose customers and compete less successfully if our ratings were to be downgraded.
Claims paying ability, financial strength, and debt ratings by recognized rating organizations are an increasingly important factor in establishing the competitive position of insurance companies.
We are also subject to risks inherent in the packaging and distribution of pharmaceuticals and other health care products, including the application of state laws and regulations related to the operation of internet a…
In some situations, we have contracts with individual or groups of primary care providers for an actuarially determined, fixed fee per month to provide a basket of required medical services to our members.
Certain of our healthcare services businesses require a Certificate of Need, or CON, to operate in certain states.
As a corporate entity, Humana Inc.
Medicare payment rates and increasing our expenses associated with assessments); our financial position (including our ability to maintain the value of our goodwill); and our cash flows.
It is reasonably possible that these laws and regulations, as well as other current or future legislative, judicial or regulatory changes, including restrictions on our ability to manage our provider network, market a…
•Our primary care and home solutions businesses derive a substantial portion of their revenues from third-party payors and directly from the federal and state governments through participation in fee-for-service Medic…
On September 1, 2023, Humana Inc.
We believe that the Final RADV Rule fails to address adequately the statutory requirement of actuarial equivalence and violates the Administrative Procedure Act (“APA”).
premium amount for the year under audit.
•At December 31, 2025, under our contracts with CMS we provided health insurance coverage to approximately 1.0 million individual Medicare Advantage members in Florida.
A significant portion of our revenues relates to federal and state government health care coverage programs, including the Medicare, military services, and Medicaid programs.
The health benefits industry continues to receive significant negative publicity reflecting the public perception of the industry.
In the ordinary course of our business, we process, store and transmit large amounts of data, and rely on third-party service providers to do the same, including protected personal information subject to privacy, secu…
Our business depends significantly on effective information systems and the integrity and timeliness of the data we use to run our business.
If we fail to properly maintain the integrity of our data, to strategically maintain existing or implement new information systems (including systems powered by or incorporating AI/ML), or to protect our proprietary r…
Based on 2025 Medicare Advantage Star Ratings released by CMS in October 2024, we have experienced a significant decline in the number of our Medicare Advantage members enrolled in plans rated 4-star or higher for 2025.
ratings will be maintained in the future.
other providers.
To the extent that we require a CON or other similar approvals to expand our operations, our expansion could be adversely affected by our inability to obtain the necessary approval.
statutes regarding corporate practice of medicine, fee-splitting, and similar issues.
conduct medical record reviews as part of our data and payment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment model.
•Our military services business, which accounted for approximately 1% of our total premiums and services revenue for the year ended December 31, 2024, primarily consisted of the TRICARE T2017 East Region contract.
addition, our credit ratings impact our ability to obtain future borrowings and investment capital on favorable terms.
other supply chain disruptions (including disruptions that occur as a result of catastrophes, including acts of terrorism, public health emergencies, epidemics or pandemics (such as COVID-19), or natural disasters (su…
including the elimination of the CON requirement, the intangible value associated with these CONs may be impaired.
restructuring or reorganization of our business, may result in a material adverse effect on our results of operations, financial position, or cash flows.
In 2012, CMS released an MA contract-level RADV methodology that would extrapolate the results of each CMS RADV audit sample to the audited MA contract’s entire health status-related risk adjusted
services or otherwise change our business practices, may increase the regulatory burdens under which we operate, and may require us to pay large judgments or fines.
or the security of our third-party service providers, could materially affect us due to the theft, destruction, loss, misappropriation or release of sensitive personal information, confidential information or propriet…
it harder for us to conduct our business using AI/ML, require us to retrain our AI/ML, delete data produced by our AI/ML, or prevent or limit our use of AI/ML.
Humana SEC Filings
Latest annual and quarterly reports, current reports, proxy statements and ownership filings.
| Form | Filed | Description | Document |
|---|---|---|---|
| Current report (8-K) | 2026-10-13 | Company update | View document |
| Current report (8-K) | 2026-10-09 | Company update | View document |
| Current report (8-K) | 2026-09-01 | Company update | View document |
| Quarterly report (10-Q) | 2026-07-29 | Quarter ended Jun 30, 2026 | View document |
| Current report (8-K) | 2026-07-29 | Executive change | View document |
Humana financial metrics by year
Humana in the S&P 500 rankings
- #27 by revenue as of FY2025
S&P 500 is a trademark of S&P Dow Jones Indices LLC. StockYears is not affiliated with or endorsed by S&P Dow Jones Indices.
Compare Humana with similar companies
- HUM vs CI Cigna Group
- HUM vs CNC Centene
- HUM vs ELV Elevance Health
- HUM vs UNH UnitedHealth Group